dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
  • Home
  • CompanyCureVac AG

June 22, 2022: CureVac AG

CureVac Announces Voting Results of General Meeting

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company’s annual general meeting.

Please read the whole article here

News 2022

June 8, 2022: CureVac AG

CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen

  • Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023
  • Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe
  • Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila to this key role. Myriam’s appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.

Please read the whole article here

News 2022

June 8, 2022: CureVac AG

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

  • Acquisition extends CureVac’s capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients’ immune systems to fight cancer
  • Frame’s platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigens

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

Please read the whole article here

News 2022

May 25, 2022: CureVac AG

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

  • CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone
  • The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses
  • Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and myNEO N.V., a Belgium-based immunotherapy company, today announced that they have entered into a research and option agreement. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.

Please read the whole article here

News 2022

May 25, 2022: CureVac AG

CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

  • Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza
    • CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial
  • Increasing momentum in oncology with access to neoantigen technologies to feed meaningful pipeline of cancer vaccine candidates
    • Partnership with myNEO to develop novel mRNA cancer vaccines leveraging myNEO’s advanced platform for tumor antigen discovery and selection
  • Cash position of €658.2 million as of March 31, 2022, impacted by wind-down costs for first-generation COVID-19 vaccine program

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2022 and provided a business update.

Please read the whole article here

News 2022

April 28, 2022: CureVac AG

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

  • Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
    – Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation
    – Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses
  • Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron
  • Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well as access to novel classes of antigens and antigen discovery platforms
  • Launched fully owned subsidiary, CureVac RNA Printer GmbH, to accelerate development of The RNA Printer® with dedicated infrastructure and experienced management
  • Executed contract with German government for pandemic preparedness together with GSK, providing access to developed vaccines and CureVac’s manufacturing capacity
  • Cash position of €811.5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoV

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2021 and provided a business update.

Please read the whole article here

News 2022

April 22, 2022: CureVac AG

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.

Conference call and webcast details

Please open here

News 2022

April 21, 2022: CureVac AG

CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

  • Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study
  • Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals
  • Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed with GSK, combining two mRNAs encoding for the Beta and the Delta variant.

Please read the whole article here

News 2022

April 11, 2022: CureVac AG

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

  • German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK
  • Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government access to CureVac’s manufacturing capacity until 2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the current pandemic or in future infectious disease outbreaks. By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation. Under the contract, the federal government will pay CureVac and GSK an annual standby fee after successful completion of the setup period, which requires the companies to maintain manufacturing capacity at constant readiness. By ensuring the availability of manufacturing capacities in Germany, the arrangement will significantly contribute to strengthening pandemic preparedness.

Please read the whole article here
News 2022

March 30, 2022: CureVac AG

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

  • Phase 1 dose-escalation study started at clinical sites in the U.S.
  • Milestone demonstrates CureVac’s and GSK’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.

Please read the whole article here
News 2022
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz